Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system
cells (CD4+ or T-cells) the virus typically infects. Ibalizumab is intended for use in
combination with other anti-HIV drugs in people with multi-drug resistant HIV and limited
treatment options. This study will collect further information on the safety and tolerability
of intravenously administered (IV) ibalizumab combined with an optimized background regimen
for treating multi-drug resistant HIV-1 infection, and will provide continuing access to
ibalizumab for patients completing a prior ibalizumab clinical trial.